Desirability function combining metabolic stability and functionality of peptides

Journal of Peptide Science

Volumn 17, Issue 5, 2011, Pages 398-404

  Van Dorpe, Sylvia ^a   Adriaens, Antita ^a   Vermeire, Simon ^a   Polis, Ingeborgh ^a   Peremans, Kathelijne ^a   Spiegeleer, Bart De ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

opioid receptor peptides; Blood brain barrier; Desirability; Metabolic stability; SPECT medical imaging

Indexed keywords

DERMORPHIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; IODINE 123; OPIATE PEPTIDE; PEPTIDE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; DECISION MAKING; DRUG RESEARCH; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PLASMA; PRIORITY JOURNAL;

ANIMALS; BLOOD-BRAIN BARRIER; MALE; MICE; OPIOID PEPTIDES; PEPTIDES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79953795025     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1323     Document Type: Article

References (40)

1. Spisani S, Fraulini A, Varani K, Falzarano S, Cavicchioni G. New chemotactic dimeric peptides show high affinity and potency at the human formylpeptide receptor. Eur. J. Pharmacol. 2007; 567: 171-176.
2. Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J. Pept. Sci. 2005; 11: 593-608.
3. Igarashi H, Ito T, Mantey SA, Pradhan TK, Hou W, Coy DH, Jensen RT. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors. J. Pharmacol. Exp. Ther. 2005; 315: 370-381.
4. Thomasy SM, Moeller BC, Stanley SD. Comparison of opioid receptor binding in horse, guinea pig, and rat cerebral cortex and cerebellum. Vet. Anaesth. Analg. 2007; 34: 351-358.
5. Nepomuceno D, Sutton S, Yu J, Zhu J, Liu C, Lovenberg T, Bonaventure P. Mutagenesis studies of neuropeptide S identify a suitable peptide tracer for neuropeptide S receptor binding studies and peptides selectively activating the I107 variant of human neuropeptide S receptor. Eur. J. Pharmacol. 2010; 635: 27-33.
6. Spetea M, Ötvös F, Tóth G, Nguyen TMD, Schiller PW, Vogel Z, Borsodi A. Interaction of agonist peptide [3H]Tyr-Ala-Phe-Phe-NH2 with [mu]-opioid receptor in rat brain and CHO-[mu]/1 cell line. Peptides 1998; 19: 1091-1098.
7. Vonhof S, Barone FC, Price WJ, Paakkari P, Millison JH, Feuerstein GZ, Siren ALK. Receptor binding and biological activity of the dermorphin analog Tyr-D-Arg(2)-Phe-Sar (TAPS). Eur. J. Pharmacol. 2001; 416: 83-93.
8. Medzihradszky K. The chemistry of the opioid receptor binding sites. J. Pept. Sci. 2003; 9: 333-353.
9. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Delivery Rev. 2001; 46: 247-279.
10. Egleton RD, Abbruscato TJ, Thomas SA, Davis TP. Transport of opioid peptides into the central nervous system. J. Pharm. Sci. 1998; 87: 1433-1439.
11. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. 2000; 294: 73-79.
12. Prokai L. Peptide delivery into the central nervous system: Invasive, physiological and chemical approaches. Expert Opin. Ther. Pat. 1997; 7: 233-245.
13. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010; 37: 13-25.
14. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 2000; 20: 57-76.
15. Pan WH, Tu H, Kastin AJ. Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 2006; 27: 911-916.
16. Banks WA, Kastin AJ, Coy DH. Evidence that [125I]N-Tyr-delta sleep-inducing peptide crosses the blood-brain barrier by a non-competitive mechanism. Brain Res. 1984; 301: 201-207.
17. Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl. Radiat. Isot. 2002; 57: 749-763.
18. Keresztes A, Toth G, Fulop F, Szucs M. Synthesis, radiolabeling and receptor binding of [H-3][(1S, 2R)ACPC(2)]endomorphin-2. Peptides 2006; 27: 3315-3321.
19. Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol. 2003; 21: 556-562.
20. Hau VS, Huber JD, Campos CR, Lipkowski AW, Misicka A, Davis TP. Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. J. Pharm. Sci. 2002; 91: 2140-2149.
21. Dangoor D, Biondi B, Gobbo M, Vachutinski Y, Fridkin M, Gozes I, Rocchi R. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. J. Pept. Sci. 2008; 14: 321-328.
22. Krondahl E, von Euler-Chelpin H, Orzechowski A, Ekström G, Lennernäs H. In vitro metabolism of opioid tetrapeptide agonists in various tissues and subcellular fractions from rats. Peptides 2001; 22: 613-621.
23. Gentilucci L. New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr. Top. Med. Chem. 2004; 4: 19-38.
24. Biondi L, Filira F, Giannini E, Gobbo M, Lattanzi R, Negri L, Rocchi R. Novel glycosylated (LyS(7))-dermorphin analogues: synthesis, biological activity and conformational investigations. J. Pept. Sci. 2007; 13: 179-189.
25. Izdebski J, Kunce D, Schiller PW, Chung NN, Gers T, Zelman M, Grabek M. Synthesis and biological activity of homoarginine-containing opioid peptides. J. Pept. Sci. 2007; 13: 27-30.
26. Mosnaim AD, Puente J, Tse R, Wolf ME. In vitro human brain methionine-enkephalin metabolism. FASEB J. 2005; 19: A509-A509.
27. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B. In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides 2008; 29: 1740-1748.
28. Van Dorpe S, Adriaens A, Polis I, Peremans K, Van Bocxlaer J, De Spiegeleer B. Analytical characterization and comparison of the blood-brain barrier permeability of eight opioid peptides. Peptides 2010; 31: 1390-1399.
29. Deming SN. Multiple-criteria optimization. J. Chromatogr. 1991; 550: 15-25.
30. Derringer G, Suich R. Simultaneous-optimization of several response variables. J. Qual. Technol. 1980; 12: 214-219.
31. Van Dorpe S, Vergote V, Pezeshki A, Burvenich C, Peremans K, De Spiegeleer B. Hydrophilic interaction LC of peptides: columns comparison and clustering. J. Sep. Sci. 2010; 33: 728-739.
32. Ekins S, Honeycutt JD, Metz JT. Evolving molecules using multi-objective optimization: applying to ADME/Tox. Drug Discov. Today 2010; 15: 451-460.
33. De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich C. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case. Anal. Biochem. 2008; 376: 229-234.
34. Chen WD, Lee W, Mulliss CL. On the rounding rules for logarithmic and exponential operations. Chin. J. Phys. 2005; 43: 1017-1034.
35. Safa F, Hadjmohammadi MR. Simultaneous optimization of the resolution and analysis time in micellar liquid chromatography of phenyl thiohydantoin amino acids using Derringer's desirability function. J. Chromatogr., A 2005; 1078: 42-50.
36. Derringer GC. A balancing act-optimizing a product's properties. Qual. Prog. 1994; 27: 51-58.
37. Aldrich JV, Patkar KA, McLaughlin JP. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 18396-18401.
38. Fichna J, Do-Rego JC, Chung NN, Costentin J, Schiller PW, Janecka A. [Dmt(1), D-1-Nal(3)]morphiceptin, a novel opioid peptide analog with high analgesic activity. Peptides 2008; 29: 633-638.
39. Janecka A, Perlikowska R, Gach K, Wyrebska A, Fichna J. Development of opioid peptide analogs for pain relief. Curr. Pharm. Des. 2010; 16: 1126-1135.
40. Lukowiak M, Kosson P, Hennink WE, Lipikowski AW. Synthesis and pharmacological properties of a new fluorescent opioid peptide analog. Pharmacol. Rep. 2009; 61: 727-731.